{"id":"tapered-doses-of-tnfi","safety":{"commonSideEffects":[{"rate":null,"effect":"Disease flare upon dose reduction"},{"rate":null,"effect":"Infection (upper respiratory, tuberculosis reactivation)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF inhibitors (TNFi) block tumor necrosis factor-alpha, a key inflammatory cytokine. Tapering involves systematically reducing the dose while monitoring for disease flare to identify the minimum effective dose, potentially reducing infection risk and other adverse effects associated with prolonged TNF blockade.","oneSentence":"Tapered doses of TNF inhibitors gradually reduce the dose of anti-TNF therapy to assess disease control and minimize long-term immunosuppression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:10.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis in remission or low disease activity"},{"name":"Inflammatory bowel disease in remission"},{"name":"Ankylosing spondylitis in remission"}]},"trialDetails":[{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%)","adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%)","certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%)","golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%)","infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%)"],"phase":"marketed","status":"active","brandName":"Tapered doses of TNFi","genericName":"Tapered doses of TNFi","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tapered doses of TNF inhibitors gradually reduce the dose of anti-TNF therapy to assess disease control and minimize long-term immunosuppression. Used for Rheumatoid arthritis in remission or low disease activity, Inflammatory bowel disease in remission, Ankylosing spondylitis in remission.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}